Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 27, 2021 16:35 ET | Source: Applied Genetic Technologies Corporation

AGTC Announces Proposed Public Offering of Common Stock and Warrants

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of...
January 27, 2021 16:19 ET | Source: Applied Genetic Technologies Corporation

AGTC Announces First Reported Improvements in Visual Sensitivity for Achromatopsia (ACHM) patients from its Ongoing Clinical Trials

-Preliminary results suggest sustained improvements to 12-months in visual sensitivity, as measured by full field static perimetry, supported in some patients by other endpoints--Company plans longer...
January 06, 2021 16:01 ET | Source: Applied Genetic Technologies Corporation

AGTC to Participate in the H.C. Wainwright BioConnect 2021 Conference

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated...
November 16, 2020 16:05 ET | Source: Applied Genetic Technologies Corporation

AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2020

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of...
November 11, 2020 07:00 ET | Source: Applied Genetic Technologies Corporation

AGTC Reports Additional Positive Data from its Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa

- Durable improvements observed in visual sensitivity and visual acuity over a wide dose-range with a favorable safety profile - - Recent FDA interactions clarify clinically meaningful improvement on...
November 10, 2020 16:05 ET | Source: Applied Genetic Technologies Corporation

AGTC to Host Conference Call on November 11 at 8:00 am ET to Discuss XLRP 12-Month Data and Full 6-Month Data from Highest Dose Groups of its Ongoing Phase 1/2 Clinical Trial

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of...
October 21, 2020 07:00 ET | Source: Applied Genetic Technologies Corporation

AGTC to Participate in Cantor Fitzgerald Virtual Panel: Key Considerations for Gene Therapy Manufacturing and Platforms

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated...
October 08, 2020 07:00 ET | Source: Applied Genetic Technologies Corporation

AGTC to Present at Upcoming Virtual Conferences

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated...
October 07, 2020 07:00 ET | Source: Applied Genetic Technologies Corporation

AGTC Joins the My Retina Tracker® Program as a New Scientific Collaborator

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (AGTC), Blueprint Genetics, and Foundation Fighting Blindness, announce today that...
September 09, 2020 07:00 ET | Source: Applied Genetic Technologies Corporation

AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020

- Planned Phase 2/3 trial expected to include approximately 60 patients and a responder analysis based on at least 7 decibel improvement in visual sensitivity in at least 5 loci across two active dose...